Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service BPH procedures cases in Montana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 17 | 1,595 | 21% |
| 2020 | 13 | 1,316 | 22% |
| 2021 | 20 | 1,515 | 25% |
TURP, laser enucleation and vaporization, UroLift, Rezum. Professional codes (what the surgeon bills): CPT 52601, 52648, 52649, 52441, 52442, 53854, 55874.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 93% of the cases CMS names in Montana; 7 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 202 | 14,148−8%/yr | −8%/yr | 4.2 | 48% | 14,100 in 2030−0.1%/yr |
| Arizona | 79 | 6,117−8.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 21 | 782−2.2%/yr | −2.2%/yr | 4.11.1× | 2% | 830 in 2030+1%/yr |
| Hysterectomy, hysteroscopy & ablation |
BPH procedures in every state, and its device makers · Every procedure market in Montana · Every state · Compare with California
| 2024 |
| 679 |
| 32% |
| 2025 est. | ≈ 550 | – |
| 2026 est. | ≈ 560 | – |
| 2022 | 19 | 1,159 | 27% |
| 2023 | 14 | 884 | 30% |
| 2024 | 12 | 679 | 32% |
| 2025 from claims | – | 547 442–642 | 32% |
| 2026 forecast | – | 558 437–701 | 32% |
| 2027 forecast | – | 565 419–746 | 32% |
| 2028 forecast | – | 571 404–788 | 33% |
| 2029 forecast | – | 578 393–828 | 33% |
| 2030 forecast | – | 584 383–867 | 34% |
In 2025, 6% inpatient hospital, 87% hospital outpatient, 7% office.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~560 | ~34 | ~490 | ~32 |
| 2027 · ~560 | ~34 | ~500 | ~28 |
| 2028 · ~570 | ~35 | ~510 | ~27 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: office about 5% (7% in 2025), hospital outpatient about 89% (87% in 2025).
| −8.2%/yr |
| 8.2 |
| 55% |
| 6,220 in 2030+0.3%/yr |
| Washington | 49 | 3,507−5.1%/yr | −5.1%/yr | 4.5 | 27% | 3,370 in 2030−0.6%/yr |
| Colorado | 49 | 2,851−4%/yr | −4%/yr | 5.8 | 43% | 2,530 in 2030−2%/yr |
| Oregon | 25 | 1,987−8.3%/yr | −8.3%/yr | 4.7 | 44% | 1,720 in 2030−2.4%/yr |
| Utah | 29 | 1,113−15%/yr | −15%/yr | 5.1 | 14% | 1,080 in 2030−0.5%/yr |
| Idaho | 17 | 1,020−1.6%/yr | −1.6%/yr | 5.0 | 38% | 1,180 in 2030+2.4%/yr |
| Nevada | 22 | 901−13%/yr | −13%/yr | 3.1 | 60% | 1,050 in 2030+2.5%/yr |
| Alaska | 6 | 477+20%/yr | +20%/yr | 4.0 | 59% | 640 in 2030+5%/yr |
| New Mexico | 10 | 453−21%/yr | −21%/yr | 2.0 | 7% | 410 in 2030−1.6%/yr |
| Hawaii | 5 | 293−11%/yr | −11%/yr | 2.3 | 43% | 390 in 2030+5%/yr |
| Wyoming | 4 | 186−7.9%/yr | −7.9%/yr | 1.7 | 39% | 240 in 2030+4.1%/yr |
| 7 |
| 426+5.8%/yr |
| +5.8%/yr |
| 2.41.0× |
| 8% |
| 720 in 2030+9.1%/yr |
| Incontinence, prolapse & sacral neuromodulation | 6 | 361+0.1%/yr | +0.1%/yr | 1.91.0× | 0% | 370 in 2030+0.3%/yr |
| Prostatectomy & nephrectomy | 6 | 237−1%/yr | −1%/yr | 1.31.1× | 0% | 280 in 2030+2.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Teleflex leads with 84% of company spending on these surgeons in 2025, +8 pts on 2024.
In 2025, 4 companies reported engagement with Montana’s surgeons worth $1,743 in consulting, speaking, meals and travel tied to these products, about $145 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.